title: Better performance of CARs deprived of the PD-1 brake.
abstract: Immunotherapies often permit combinations to increase efficacy. Two approaches are currently leading our field: adoptive therapy with T cells transfected with chimeric antigen receptors and monoclonal antibodies blocking the PD-1/PD-L1 (B7-H1) axis. In this issue of Clinical Cancer Research, preclinical evidence for a synergistic combination of such approaches is reported.
authors.affiliation: Authors' Affiliation: Center for Applied Medical Research, CIMA and University Clinic, University of Navarra, Pamplona, Spain.
authors.forename: Aizea
authors.initials: A
authors.lastname: Morales-Kastresana
authors.forename: Sara
authors.initials: S
authors.lastname: Labiano
authors.forename: José I
authors.initials: JI
authors.lastname: Quetglas
authors.forename: Ignacio
authors.initials: I
authors.lastname: Melero
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000276:immunology*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor